viewArix Bioscience PLC

Arix Bioscience Plc - 2019 Capital Markets Day

Arix Bioscience plc

2019 Capital Markets Day

Oncology Portfolio Spotlight

(“Arix”, LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, is hosting its 2019 Capital Markets Day from today Thursday, 3 in ., :LONDON3 October 2019Arix Bioscience plc1:45pmOctober 2019rdLondon

The Capital Markets Day, focused on Arix’s oncology portfolio, will be an opportunity for institutional investors, analysts and media to learn more about Arix, its portfolio companies and strategy.

The event will include presentations from Joe Anderson, Chief Executive Officer and Jonathan Tobin, Investment Director, along with presentations from the oncology portfolio companies, a panel discussion and Q&A. 

No new material information will be disclosed.

Presenters at the Arix Capital Markets Day will include:

Event details

Registration for the event will start at followed by a series of presentations and Q&A sessions starting promptly from . The day will conclude with a networking session from approximately .1:45pm BST2:10pm BST5:30pm BST

A webcast of the event, with presentation slides, will be available on the Arix after the event.website



For more information on Arix, please contact:

Arix Bioscience plc

, Head of Investor RelationsCharlotte Parry

+44 (0)20 7290 1072

[email protected]

Optimum Strategic Communications

Mary Clark,Supriya Mathur

T: +44 (0) 203 950 9144

[email protected]

AboutArix Bioscience plc

is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.Arix Bioscience plc

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.


--  , PhD, CEO of 

    --  , PhD, Investment Director, 

    --  , PhD, Entrepreneur in Residence, 
        and Executive Chairman, 

    --   los Pinos, PhD, CEO of Aura Biosciences

    --  , PhD, CEO and Chairman of  (NASDAQ: AUTL)

    --  , President and CEO of VelosBio

    --  , PhD, CEO of Artios Pharma

    --  , PhD, President and CEO of  (NASDAQ:
        HARP)Joe AndersonJonathan TobinChristian SchetterSTipe TherapeuticsElisabet deChristian ItinDave JohnsonNiall MartinGerald McMahonArix Bioscience plcArix Bioscience plcArix Bioscience plcAutolusHarpoon Therapeutics

Quick facts: Arix Bioscience PLC

Price: 86.5

Market: LSE
Market Cap: £117.3 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Aura Biosciences reports positive clinical data on its eye cancer treatment...

Aura Biosciences Inc CEO Elisabet de los Pinos tells Proactive Investors the biotech has reported positive clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light- activated AU-011, its lead product candidate for the treatment of choroidal melanoma, a type...

on 11/06/2018